Sanofi and CD&R entered into exclusive negotiations for the potential sale and purchase of a 50% controlling stake in Opella.

Regeneron spent $5 billion repurchasing shares from Sanofi in May 2020 and $900 million repurchasing global rights to Libtayo in July 2022, yet a windfall from sales of its Covid antibody cocktail as ...

New data released by Merck suggests AstraZeneca and Sanofi’s Beyfortus, the monoclonal antibody injection that protects ...

In 2022, the global monoclonal antibodies market size was valued at USD 186 billion in 2021. The market is projected to ...

Truist lowered the firm’s price target on Regeneron (REGN) to $1,137 from $1,200 and keeps a Buy rating on the shares after ...

Patients with inflammatory bowel disease (IBD) who initially responded to the investigational monoclonal antibody ...

Despite uncertainty around who will sit in The White House in January and what ramifications they may bring, the industry’s ...

The long-term risk of distant recurrence for women with early breast cancer has declined significantly, a decades-long ...

US biotech major Amgen (Nasdaq: AMGN) has further strengthened the growing evidence for the use of Uplizna (inebilizumab-cdon ...

A new study found that risk factors for diabetes in patients with the genetic condition are the same as for those in the ...

The global pharmaceutical industry will generate more than $1.2 trillion in sales in 2025, according to Statista. A large portion of that figure is from the oncology segment, which is expected ...

PARIS, Oct 11 (Reuters) - Sanofi (SASY.PA), opens new tab has entered into talks to sell a controlling 50% stake in its consumer health business Opella to U.S. private equity firm Clayton Dubilier ...